Contact our breast care nurses 0808 800 6000


EndoPredict is a type of test that predicts how likely breast cancer is to spread to somewhere else in the body. Read on to learn about the test and discover whether it could be useful to you.

1. What is the EndoPredict test?

EndoPredict is a test that predicts how likely breast cancer is to spread to somewhere else in the body (secondary breast cancer) within 10 years of diagnosis, in people who will be taking hormone therapy for at least 5 years.

2. Who is EndoPredict for?

The test is suitable for people recently diagnosed with early stage breast cancer that:

  • Has not spread to the under the arm
  • Is oestrogen receptor positive (ER-positive)
  • Is HER2 negative (HER2-negative)

Sometimes the test may be considered for people whose breast cancer affects 1 to 3 lymph nodes under the arm. 

The test is not suitable for people whose breast cancer is oestrogen receptor negative or HER2-positive. 

3. Why is it used?

Your specialist may recommend the EndoPredict test to help decide if other treatments, particularly chemotherapy, are needed.  

Chemotherapy may be given after surgery to reduce the risk of breast cancer coming back in future.

Whether you’re offered chemotherapy depends on a number of features of your breast cancer. These include:

  • The size and grade of the cancer
  • Whether it has spread to any of the lymph nodes under the arm
  • Whether the cancer is hormone receptor and HER2 positive or negative

For some people the benefit of chemotherapy is clear, but for others it’s less clear.

4. How does it work?

The test is done on a small amount of breast cancer tissue already removed (for example during a or surgery). The tissue is sent to a laboratory, usually outside your local hospital and sometimes in Germany, where the test is carried out.

The test looks at groups of genes found in breast cancer and features of the breast cancer to produce a score.

The results are given separately from your pathology report and are sent to your specialist usually within 7 to 10 days.

If your specialist has recommended you have hormone therapy before surgery, the test must be done on the tissue removed by a core biopsy before you start hormone therapy. 

5. EndoPredict score

The test gives a score, known as an EPclin Risk score, that is reported as either low or high risk. 

Your specialist will use the score, along with other information about your breast cancer, to help decide what treatment to recommend. 

Low risk

A low risk score means it’s unlikely the breast cancer will spread to somewhere else in the body in the next 10 years.

Most people with a low risk score will not need chemotherapy.  

High risk

A high risk score means it’s more likely the breast cancer will spread to somewhere else in the body in the next 10 years.

Chemotherapy is recommended for most people with a high risk score.  

6. Availability and cost

If EndoPredict is suitable for you, it’s usually available on the NHS across the UK.

Most private healthcare companies will also cover the cost of the test.

You can also pay for the test yourself, but your treatment team will need to order the test for you and will be sent the results to discuss with you. It costs around £1,500.

Was this helpful?

Was this helpful?
Please tell us what you liked about it.
Please tell us why.
We’re sorry you didn’t find this helpful.
Please do not include personal details and be aware we cannot respond to comments.

Quality assurance

Last reviewed in October 2021. The next planned review begins in October 2023.

  • support-cta-icon-telephone

    Call our free helpline

    If you have any concerns about breast cancer, or just want to talk, our specialist nurses are here for you.

    Lines open: Monday to Friday - 9am to 4pm; Saturday - 9am to 1pm

  • support-cta-icon-email

    Explore ways to talk to our nurses

    It can be difficult to talk to someone in person about breast cancer concerns. Explore other ways you can ask a question.

Share this page